Abstract
Non-dopaminergic therapies are of potential interest in the treatment of Parkinson's disease given the complications associated with current dopamine-replacement therapies. In this study we demonstrate that SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3, 5-tetrahydropyrrol[2,3-f]indole) (20 mg/kg) enhanced the actions of the dopamine D(1) receptor agonist, SKF 82958 ((+)-6-chloro-7, 8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide) (1 mg/kg), in eliciting locomotion in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. This action was only seen following prior priming with L-DOPA (L-3, 4-dihydroxyphenylalanine). SB 206553 had no effect on rotational behaviour when given alone. 5-HT(2C) receptor antagonists may have potential as a means of reducing reliance on dopamine replacement in the treatment of Parkinson's disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antiparkinson Agents / pharmacology
-
Behavior, Animal / drug effects*
-
Benzazepines / pharmacology
-
Disease Models, Animal
-
Dopamine Agonists / pharmacology
-
Indoles / pharmacology
-
Levodopa / pharmacology
-
Locomotion / drug effects
-
Male
-
Oxidopamine / adverse effects
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy
-
Parkinson Disease, Secondary / physiopathology
-
Pyridines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Receptor, Serotonin, 5-HT2C
-
Receptors, Dopamine D1 / agonists*
-
Receptors, Serotonin / drug effects*
-
Serotonin Antagonists / pharmacology*
Substances
-
Antiparkinson Agents
-
Benzazepines
-
Dopamine Agonists
-
Indoles
-
Pyridines
-
Receptor, Serotonin, 5-HT2C
-
Receptors, Dopamine D1
-
Receptors, Serotonin
-
Serotonin Antagonists
-
Levodopa
-
SK&F 82958
-
Oxidopamine
-
SB 206553